§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇨🇦Canada	🇬🇧United Kingdom
Authority & dossier
Regulatory authority	HC HPFB	MHRA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA, EMA, MHRA, TGA +2	FDA, EMA, Health Canada, Swissmedic +4
Lead pathway (timeline & fees) — New Drug Submission (NDS) · International Recognition Procedure (IRP)
Pathway name	New Drug Submission (NDS)	International Recognition Procedure (IRP)
Approval timeline	300–365 days	60–110 days
Application fee	CAD 539,663	GBP 35,305
Annual renewal	CAD 4,129	GBP 0
Local representative	Not required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Not required
MAH & local presence
Local entity required	No	Yes
Local responsible person	Yes	Yes
RP role	Canadian Senior Officer responsible for the establishment licence, Quality Assurance Person (QA) for batch release, and Senior Medical Adviser for drug safety reporting. Canadian importer DEL holder takes physical receipt of imported products.	Qualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.
Accelerated pathways
Designations available	4 designations	4 designations
Examples	Priority Review, Notice of Compliance with Conditions (NOC/c), Advance Consideration under Notice of Compliance +1	Early Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1
Post-approval lifecycle
Variations framework	Three categories: Notifiable Changes (notification, certain low-risk changes), Supplemental NDS (S/NDS — prior approval, mid-tier and major changes), and Annual Notification (consolidates minor administrative updates). The Post-NOC Changes Quality Document and Post-NOC Changes Safety and Efficacy Document specify classification.	Variations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.
Renewal cycle	No periodic renewal of NDS — DIN remains valid indefinitely subject to compliance and payment of annual Right to Sell fee. Annual Drug Notification Form required to confirm marketing status.	Initial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.
Pharmacovigilance	Vanessa's Law (Protecting Canadians from Unsafe Drugs Act, 2014) significantly strengthened post-market authorities — including mandatory hospital ADR reporting (in force since 2019), authority to require label changes, and authority to require post-market studies. PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs) on harmonised birth dates. Canada Vigilance is the spontaneous reporting system; MedEffect Canada provides safety communications.	MHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–30 days	30–60 days
GCP standard	ICH E6(R3) — Health Canada adopted via guidance update 2025; Division 5 FDR	ICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	No
HTA required	Yes	Yes
HTA body	Canada's Drug Agency (formerly CADTH, rebrand 2024); INESSS for Quebec	NICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

CanadaHC HPFB
United KingdomMHRA

English submissions

CanadaYes
United KingdomYes

CTD accepted

CanadaYes
United KingdomYes

eCTD accepted

CanadaYes
United KingdomYes

Reliance pathway

CanadaAvailable
United KingdomAvailable

Reference agencies

CanadaFDA, EMA, MHRA, TGA +2
United KingdomFDA, EMA, Health Canada, Swissmedic +4

Lead pathway (timeline & fees) — New Drug Submission (NDS) · International Recognition Procedure (IRP)

Pathway name

CanadaNew Drug Submission (NDS)
United KingdomInternational Recognition Procedure (IRP)

Approval timeline

Canada300–365 days
United Kingdom60–110 days

Application fee

CanadaCAD 539,663
United KingdomGBP 35,305

Annual renewal

CanadaCAD 4,129
United KingdomGBP 0

Local representative

CanadaNot required
United KingdomNot required

Local manufacturing

CanadaNot required
United KingdomNot required

GMP inspection

CanadaRequired
United KingdomNot required

MAH & local presence

Local entity required

CanadaNo
United KingdomYes

Local responsible person

CanadaYes
United KingdomYes

RP role

CanadaCanadian Senior Officer responsible for the establishment licence, Quality Assurance Person (QA) for batch release, and Senior Medical Adviser for drug safety reporting. Canadian importer DEL holder takes physical receipt of imported products.
United KingdomQualified Person (Pharmacovigilance) — QPPV — must reside in the UK or EEA. UK Responsible Person (Import) for batch certification of products imported into GB. Local pharmacovigilance contact in the UK required for risk minimisation activities.

Accelerated pathways

Designations available

Canada4 designations
United Kingdom4 designations

Examples

CanadaPriority Review, Notice of Compliance with Conditions (NOC/c), Advance Consideration under Notice of Compliance +1
United KingdomEarly Access to Medicines Scheme (EAMS), Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +1

Post-approval lifecycle

Variations framework

CanadaThree categories: Notifiable Changes (notification, certain low-risk changes), Supplemental NDS (S/NDS — prior approval, mid-tier and major changes), and Annual Notification (consolidates minor administrative updates). The Post-NOC Changes Quality Document and Post-NOC Changes Safety and Efficacy Document specify classification.
United KingdomVariations classified per UK Variations Regulations (mirroring EU Reg 1234/2008): Type IA, IAIN, IB, II, and Extensions. MHRA Worksharing available for grouped variations across multiple authorisations.

Renewal cycle

CanadaNo periodic renewal of NDS — DIN remains valid indefinitely subject to compliance and payment of annual Right to Sell fee. Annual Drug Notification Form required to confirm marketing status.
United KingdomInitial 5-year renewal; thereafter MA is granted for unlimited duration unless MHRA determines on PV grounds that one further 5-year renewal is justified.

Pharmacovigilance

CanadaVanessa's Law (Protecting Canadians from Unsafe Drugs Act, 2014) significantly strengthened post-market authorities — including mandatory hospital ADR reporting (in force since 2019), authority to require label changes, and authority to require post-market studies. PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs) on harmonised birth dates. Canada Vigilance is the spontaneous reporting system; MedEffect Canada provides safety communications.
United KingdomMHRA operates the Yellow Card Scheme for ADR reporting. PSURs follow the EU Reference Date list pre-Brexit, with MHRA UK-specific PSUR list since 2021. RMPs required for new MAs and significant variations. Black triangle (▼) for additional monitoring.

Unlicensed access

Named Patient Supply

CanadaAvailable
United KingdomAvailable

Compassionate Use

CanadaAvailable
United KingdomAvailable

Emergency Import

CanadaAvailable
United KingdomAvailable

Parallel Import

CanadaNot permitted
United KingdomPermitted

Clinical trials

CTA approval

CanadaRequired
United KingdomRequired

Ethics approval

CanadaYes
United KingdomYes

CTA timeline

Canada30–30 days
United Kingdom30–60 days

GCP standard

CanadaICH E6(R3) — Health Canada adopted via guidance update 2025; Division 5 FDR
United KingdomICH E6(R3) (MHRA adopted via Good Clinical Practice Guide; UK statutory instruments 2004/1031 as amended)

Pricing & reimbursement

Price regulation

CanadaRegulated
United KingdomRegulated

Reference pricing

CanadaYes
United KingdomNo

HTA required

CanadaYes
United KingdomYes

HTA body

CanadaCanada's Drug Agency (formerly CADTH, rebrand 2024); INESSS for Quebec
United KingdomNICE (England, Wales, NI), SMC (Scotland), AWMSG (Wales)